Keensight to acquire majority stake in Symeres to expand drug discovery

upland-software-buys-bluevenn-for-52mn-to-boost-customer-engagement

Keensight Capital, a European growth buyout investor with expertise in technology and healthcare, has inked an agreement to invest in Symeres- a prominent European drug discovery Contract Development and Manufacturing Organization (CDMO) and a Contract Research Organization (CRO).

As per the deal, Keensight Capital is slated to purchase a majority share in Symeres from the Gilde Healthcare Pvt. Equity fund- a prominent European specialist healthcare investor. 

Incorporated in the year 1997, Symeres is one the most prominent European small molecule CDMO and CRO, offering R&D services for preclinical drug discovery, Phase I & II clinical trial drug development as well as manufacturing services for many leading pharmaceutical and biopharmaceutical companies worldwide.

Its highly advanced services cover complex synthetic chemistry, small molecule optimization solutions, solid-state chemistry, ADME- Tox technology, and drug synthesis & route scouting up to GMP production.

Based in Netherlands, Symeres employs more than 500 people, most of whom are Ph.D. scientists that operate in more than 6 sites across the Netherlands, Finland, Czech Republic, and Sweden, coupled with a business development office in the U.S. The company claims to be achieving more than €70 million in terms of sales in 2021. 

Reportedly, Keensight Capital aims at supporting the management team in pursuing and driving the organic and external growth of the company, while providing clients with industry-leading service that the company is known for.  

According to Dr. Eelco Ebbers, CEO and co-founder, Symeres, with the investment from Keensight Capital, the firm plans to extend and expand its range of drug discovery along with development services.  

Rafael Natanek, Partner, Gilde Healthcare, was quoted stating that the firm has played an integral role in the international expansion of Symeres, taking part in the merger of Mercachem with Syncom in the year 2017, and is delighted to have collaborated with management to support the growth of Symeres.

Source  Credit: https://www.globenewswire.com/news-release/2021/05/25/2235078/0/en/Keensight-Capital-to-Acquire-a-Majority-Stake-in-Leading-European-CRO-and-CDMO-Symeres-from-Gilde-Healthcare-Private-Equity.html